You are here

Article Text

Article menu
Download PDFPDF
Letter
RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation
  1. A J Ashcroft1,
  2. S R Carding2
  1. 1Academic Unit of Haematology and Oncology, School of Medicine, University of Leeds, Leeds, UK
  2. 2School of Biochemistry and Molecular Biology, University of Leeds, Leeds, UK
  1. Correspondence to:
    Dr A J Ashcroft
    Department of Haematology, St James’s Hospital, Leeds, UK; johnashcroftdoctors.org.uk

https://doi.org/10.1136/gut.2005.070623

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the study by Byrne and colleagues (Gut 2005;54:78–86) outlining the significant therapeutic opportunities provided by manipulation of the RANK/RANK ligand (RANKL)/osteoprotegerin (OPG) system using recombinant Fc-OPG. There are, however, a number of physiological effects of OPG that were not discussed and which demonstrate the depth of influence of the RANK/RANKL/OPG system on both inflammatory disease and possibly immune surveillance …

    View Full Text

    Footnotes

    • Conflict of interest: None declared.

    Linked Articles